September 15, 2012Annals of the Rheumatic DiseasesOpen Access

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks

View Full Paper

Ask AI

Bookmark

Abstract

Golimumab monotherapy (50 and 100 mg) was effective in reducing the signs and symptoms of RA in Japanese patients with active disease despite DMARD treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Takeuchi et al. (2012) studied this question.

synapsesocial.com/papers/69dbc31d3d9adb00e7684eda https://doi.org/10.1136/annrheumdis-2012-201796

View Full Paper

Ask AI

Bookmark

Abstract

Golimumab monotherapy (50 and 100 mg) was effective in reducing the signs and symptoms of RA in Japanese patients with active disease despite DMARD treatment.

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks

Abstract

Discussion

Cite This Study

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks

Abstract

Discussion

Cite This Study

Keep reading

Keep reading